AstraZeneca's Lynparza gets EU nod as first-line ovarian cancer maintenance treatment

British drugmaker AstraZeneca Plc on Tuesday said its cancer medicine Lynparza was approved as a first-line maintenance treatment for a type of advanced ovarian cancer by the European Commission, following a panel's consent in April.